# Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine

> **NCT02867709** · PHASE3 · COMPLETED · sponsor: **Allergan** · enrollment: 1686 (actual)

## Conditions studied

- Migraine, With or Without Aura

## Interventions

- **DRUG:** Ubrogepant
- **DRUG:** Placebo-matching Ubrogepant

## Key facts

- **NCT ID:** NCT02867709
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-26
- **Primary completion:** 2018-01-25
- **Final completion:** 2018-02-26
- **Target enrollment:** 1686 (ACTUAL)
- **Last updated:** 2019-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02867709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02867709, "Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02867709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*